Detalhe da pesquisa
1.
The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms.
Blood
; 140(7): 716-755, 2022 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35671390
2.
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
Ann Hematol
; 103(1): 105-116, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38036712
3.
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Cancer
; 129(15): 2308-2320, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37078412
4.
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Blood
; 136(1): 71-80, 2020 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32244252
5.
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
Ann Hematol
; 101(8): 1689-1701, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35488900
6.
A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
Am J Hematol
; 96(2): 226-233, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33125764
7.
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.
Blood
; 132(11): 1125-1133, 2018 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30045838
8.
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.
Blood
; 131(4): 387-396, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29196412
9.
Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study.
Am J Hematol
; 94(7): 794-802, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31021005
10.
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 19(7): 889-903, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29859851
11.
Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia.
Haematologica
; 108(12): 3460-3463, 2023 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37345485
12.
Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study.
Am J Hematol
; 97(11): E422-E425, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36053878
13.
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
Blood
; 123(21): 3239-46, 2014 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-24687088
14.
Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population.
Biol Blood Marrow Transplant
; 21(1): 89-96, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25445641
15.
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Blood Adv
; 8(2): 429-440, 2024 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37871309
16.
Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.
Blood Adv
; 7(20): 6048-6054, 2023 10 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37459200
17.
RNAi screen for rapid therapeutic target identification in leukemia patients.
Proc Natl Acad Sci U S A
; 106(21): 8695-700, 2009 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-19433805
18.
GABA-A Receptor Encephalitis After Autologous Hematopoietic Stem Cell Transplant forMultiple Myeloma: Three Cases and Literature Review.
Neurol Neuroimmunol Neuroinflamm
; 9(6)2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36028311
19.
A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm.
Blood Adv
; 6(2): 405-409, 2022 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34649277
20.
AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome.
Leukemia
; 36(3): 664-674, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34671111